- Home
- SRTS vs AGEN Comparison
SRTS vs AGEN Comparison
Compare SRTS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- AGEN
- Stock Information
- Founded
- SRTS 2010
- AGEN 1994
- Country
- SRTS United States
- AGEN United States
- Employees
- SRTS N/A
- AGEN N/A
- Industry
- SRTS Medical/Dental Instruments
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRTS Health Care
- AGEN Health Care
- Exchange
- SRTS Nasdaq
- AGEN Nasdaq
- Market Cap
- SRTS 118.2M
- AGEN 96.2M
- IPO Year
- SRTS 2016
- AGEN 2000
- Fundamental
- Price
- SRTS $6.77
- AGEN $3.15
- Analyst Decision
- SRTS Strong Buy
- AGEN Buy
- Analyst Count
- SRTS 2
- AGEN 3
- Target Price
- SRTS $12.50
- AGEN $10.50
- AVG Volume (30 Days)
- SRTS 244.3K
- AGEN 444.4K
- Earning Date
- SRTS 02-06-2025
- AGEN 11-12-2024
- Dividend Yield
- SRTS N/A
- AGEN N/A
- EPS Growth
- SRTS N/A
- AGEN N/A
- EPS
- SRTS 0.57
- AGEN N/A
- Revenue
- SRTS $41,308,000.00
- AGEN $160,427,000.00
- Revenue This Year
- SRTS $65.04
- AGEN N/A
- Revenue Next Year
- SRTS $24.87
- AGEN $36.13
- P/E Ratio
- SRTS $11.51
- AGEN N/A
- Revenue Growth
- SRTS 65.62
- AGEN 59.00
- 52 Week Low
- SRTS $2.61
- AGEN $2.50
- 52 Week High
- SRTS $9.33
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- SRTS 40.52
- AGEN 49.83
- Support Level
- SRTS $6.38
- AGEN $2.96
- Resistance Level
- SRTS $7.62
- AGEN $3.70
- Average True Range (ATR)
- SRTS 0.43
- AGEN 0.25
- MACD
- SRTS -0.05
- AGEN 0.05
- Stochastic Oscillator
- SRTS 29.55
- AGEN 50.89
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).